ES2063326T3 - Conjugados de polimixina. - Google Patents

Conjugados de polimixina.

Info

Publication number
ES2063326T3
ES2063326T3 ES90810872T ES90810872T ES2063326T3 ES 2063326 T3 ES2063326 T3 ES 2063326T3 ES 90810872 T ES90810872 T ES 90810872T ES 90810872 T ES90810872 T ES 90810872T ES 2063326 T3 ES2063326 T3 ES 2063326T3
Authority
ES
Spain
Prior art keywords
conjugates
polymixine
polymyxine
dextran
powerful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90810872T
Other languages
English (en)
Inventor
Dean Allen Handley
Philip Lake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Application granted granted Critical
Publication of ES2063326T3 publication Critical patent/ES2063326T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE EXPONEN LOS CONJUGADOS PORTADORES DE POLIMIXINA SOLUBLES EN AGUA TALES COMO LOS CONJUGADOS DE B-DEXTRAN POLIMIXINA. TIENEN UNA LARGA MEDIA VIDA EN LA CORRIENTE SANGUINEA Y SON SIGNIFICANTEMENTE MAS POTENTES Y MENOS TOXICOS QUE LAS POLIMIXINAS NATURALES.
ES90810872T 1989-11-15 1990-11-13 Conjugados de polimixina. Expired - Lifetime ES2063326T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43748789A 1989-11-15 1989-11-15

Publications (1)

Publication Number Publication Date
ES2063326T3 true ES2063326T3 (es) 1995-01-01

Family

ID=23736660

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90810872T Expired - Lifetime ES2063326T3 (es) 1989-11-15 1990-11-13 Conjugados de polimixina.

Country Status (17)

Country Link
EP (1) EP0428486B1 (es)
JP (1) JPH082917B2 (es)
KR (1) KR0184858B1 (es)
AT (1) ATE111746T1 (es)
AU (1) AU639952B2 (es)
CA (1) CA2029997A1 (es)
CY (1) CY2052B1 (es)
DE (1) DE69012747T2 (es)
DK (1) DK0428486T3 (es)
ES (1) ES2063326T3 (es)
HK (1) HK49696A (es)
HU (1) HU210901A9 (es)
IE (1) IE65268B1 (es)
IL (1) IL96326A (es)
MY (1) MY104520A (es)
NZ (1) NZ236050A (es)
ZA (1) ZA909187B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504824A (ja) * 1992-12-21 1996-05-28 オフィディアン ファーマシューティカルズ，インコーポレーテッド 敗血症の予防および治療
US6660267B1 (en) 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
US5545721A (en) * 1992-12-21 1996-08-13 Ophidian Pharmaceuticals, Inc. Conjugates for the prevention and treatment of sepsis
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
ES2210262T3 (es) * 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.
JP2581425B2 (ja) * 1993-11-12 1997-02-12 株式会社島津製作所 ペプチド合成用支持体及びそれを用いて製造されたペプチド
AU712981B2 (en) * 1995-03-22 1999-11-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
KR100417183B1 (ko) * 1995-03-22 2004-05-31 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 유기시아닐화제로활성화된가용성탄수화물을이용한면역원성구조체제조
US5691304A (en) * 1995-05-25 1997-11-25 Novartis Ag Improved process for preparing polymyxin B/dextran conjugates
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
US5998381A (en) * 1996-12-06 1999-12-07 Ophidian Pharmaceuticals, Inc. Compounds that bind bacterial pili
IT1312110B1 (it) 1999-05-18 2002-04-04 Istituto Biochimico Pavese Pha Addotti antibiotico-polimero polisaccaridico naturale
DE10129369C1 (de) * 2001-06-21 2003-03-06 Fresenius Kabi De Gmbh Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats
AT507846B1 (de) * 2009-01-22 2011-12-15 Fresenius Medical Care De Gmbh Sorptionsmittel für endotoxine
BR112017006848B1 (pt) * 2014-10-03 2022-10-04 Xellia Pharmaceuticals Aps Composições
JP2020503253A (ja) * 2016-10-21 2020-01-30 アルギファルマ エーエス ポリミキシン−アルギネートオリゴマー結合体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7702261L (sv) * 1976-03-02 1977-09-07 Pharmaco Inc Forfarande for att immobilisera antimikrobiella emnen
JPS5813519A (ja) * 1981-07-16 1983-01-26 Seikagaku Kogyo Co Ltd エンドトキシン吸着材及びそれを用いるエンドトキシンの除去方法
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer

Also Published As

Publication number Publication date
IL96326A0 (en) 1991-08-16
IL96326A (en) 1995-07-31
ZA909187B (en) 1992-07-29
MY104520A (en) 1994-04-30
EP0428486B1 (en) 1994-09-21
IE65268B1 (en) 1995-10-18
NZ236050A (en) 1993-04-28
HK49696A (en) 1996-03-29
HU210901A9 (en) 1995-09-28
CA2029997A1 (en) 1991-05-16
KR0184858B1 (ko) 1999-05-01
IE904105A1 (en) 1991-05-22
JPH082917B2 (ja) 1996-01-17
DK0428486T3 (da) 1995-01-09
AU639952B2 (en) 1993-08-12
EP0428486A1 (en) 1991-05-22
JPH03220198A (ja) 1991-09-27
ATE111746T1 (de) 1994-10-15
AU6655590A (en) 1991-05-23
CY2052B1 (en) 1998-04-30
DE69012747T2 (de) 1995-03-16
KR910009274A (ko) 1991-06-28
DE69012747D1 (de) 1994-10-27

Similar Documents

Publication Publication Date Title
DE60010098D1 (de) 28-epirapaloge
SV1995000010A (es) Prenda absorbente con un manejo mejorado de las emanaciones
ES2090364T3 (es) Material de implante de vascularizacion cercana.
ES2103966T3 (es) Uso de una timosina en el tratamiento de hepatitis c.
ES2151921T3 (es) Analogo de dolastatina.
ATE176587T1 (de) Verbesserte gewebestützvorrichtungen
ES2142829T3 (es) Dispositivos para llevar a cabo un procedimiento intraluminal.
DK1036058T3 (da) Adamantanderivater
DK1036059T3 (da) Adamantanderivater
CL2003002786A1 (es) Composicion liofilizada que comprende i) una epotilona y ii) manitol o una ciclodextrina y composicion liofilizada que los comprende reconstituida con solvente, util como citotoxico en el tratamiento de tumores.
DE69823725D1 (de) Selbstexpandierendes Medizingerät
CY1105112T1 (el) Διαμορφωσεις δια καταπολεμησιν ανθρωπινων φθειρων, πepιεχουσαι σπινοσυνη (spinosyn)
ES2099211T3 (es) Conjugados citomoduladores de miembros de parejas de union especifica.
MX9207074A (es) Piperazinil- y piperidinil -ciclohexanoles y composicion farmaceutica que los comprende
DE69207733D1 (de) Wiederherstellungsimplantat für Augenhöhlen
FI883653A0 (fi) Mikrobeja tappava mikroemulsio
ATE355039T1 (de) Flächiges implantat mit röntgensichtbaren elementen
DE68908087D1 (de) Dentales restaurationsmaterial.
ES2058892T3 (es) Uso de omeprazol como agente antimicrobiano.
DE59009451D1 (de) Colestyramin als lipidsenker enthaltende präparate.
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
DE59009354D1 (de) Zahnärztlicher Patientenstuhl.
ITMI951367A0 (it) Derivati della colchicina loro uso e formulazioni che li contengono
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
ATE111746T1 (de) Polymyxinkonjugate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 428486

Country of ref document: ES